Skip to main content
Search this site
Search
☰ Menu
Technologies
MiniPDX® - In-vivo 3D Organoid
MiniPDX® Methodology and Comparisons
MiniPDX® Application in Drug R&D and and Correlation with PDX
MiniPDX® for Precision Medicine
Patient-Derived Xenograft (PDX) Models
Established Patient-Derived Xenograft (PDX) Models
PDOX of Hematological Malignancies
PDOX for Brain Metastasis
Orthotopic Models
Conditionally Reprogrammed (CR) Cells
A Better Alternative to Immortalized Cell Lines
Validation of CR Cells Heterogeneity
Cell Line-Derived Xenograft (CDX) Models
Overview
Immune-Oncology Platforms
Overview
Murine/Humanized Syngeneic Models
HuPBMC Reconstituted Models
HuPBMC Cancer Co-Inoculated Models
Macrophage Involved IO Models
Dentritic Cell Involved IO Models
Car-T In Vivo Efficacy Evaluation
Oncolytic Virus In Vivo Efficacy Evaluation
OMICS Bioinformatics Analysis
Overview and Bioinformatics
Proteomics and Functional Genomic Imaging (FGI)
Imaging Mass Cytometry or CyTOF Tissue Imaging
Revolutionary OncoVee™ K-Cell 1000 Cell Kit
Solutions
Model Systems
In-Vivo Models and Studies
In-Vitro Models and Studies
By Therapeutic Areas
Preclinical Oncology Studies
Immuno-Oncology (IO) Studies
Drug Resistant Cancer Models
Rare Cancers and Genetic Alterations
Popular Expression Targets
Brain Metastasis
Hematological Malignancies (Blood Cancers)
By Research Phase
Target Identification & HIT Discovery
Lead Optimization and Preclinical Validation
Preclinical Indication Screening
Biomarker Identification for Companion Diagnosis
Clinical Testing
Resources
Downloads
Publications
Webinars
News & Events
LIDE Blog
Why LIDE
Mission for Precision Medicine
Dedicated US Leadership
Industry Thought Leadership
Highest Operational Standards
Scientist.com Partner
Model Search
Contact
Mobile Menu
Request a Quote
Technologies
MiniPDX® - In-vivo 3D Organoid
MiniPDX® Methodology and Comparisons
MiniPDX® Application in Drug R&D and and Correlation with PDX
MiniPDX® for Precision Medicine
Patient-Derived Xenograft (PDX) Models
Established Patient-Derived Xenograft (PDX) Models
PDOX of Hematological Malignancies
PDOX for Brain Metastasis
Orthotopic Models
Conditionally Reprogrammed (CR) Cells
A Better Alternative to Immortalized Cell Lines
Validation of CR Cells Heterogeneity
Cell Line-Derived Xenograft (CDX) Models
Overview
Immune-Oncology Platforms
Overview
Murine/Humanized Syngeneic Models
HuPBMC Reconstituted Models
HuPBMC Cancer Co-Inoculated Models
Macrophage Involved IO Models
Dentritic Cell Involved IO Models
Car-T In Vivo Efficacy Evaluation
Oncolytic Virus In Vivo Efficacy Evaluatoin
OMICS Bioinformatics Analysis
Overview and Bioinformatics
Proteomics and Functional Genomic Imaging (FGI)
Imaging Mass Cytometry or CyTof Tissue Imaging
Revolutionary OncoVee™ K-Cell 1000 Cell Kit
Solutions
By Model Systems
In-Vivo Models and Studies
In-Vitro Models and Studies
By Therapeutic Areas
Preclinical Oncology Studies
Immuno-Oncology (IO) Studies
Drug Resistant Cancer Models
Rare Cancers and Genetic Alterations
Popular Expression Targets
Brain Metastasis
Hematological Malignancies (Blood Cancers)
By Research Phase
Target Identification & HIT Discovery
Lead Optimization and Preclinical Drug Candidate Validation
Preclinical Indication Screening
Biomarker Identification for Companion Diagnosis
Clinical Testing Services
Resources
Downloads
Publications
Webinars
News & Events
LIDE Blog
WHY LIDE
Mission for Precision Medicine
Dedicated US Leadership
Industry Thought Leadership
Highest Operational Standards
Scientist.com Partner
Model Search
Contact
Request a Quote
Downloads